Newly Diagnosed PatientsOlder PatientsAE & ComorbiditiesPerinatal CareTrans HealthAntiretroviral TherapyQuiz Yourself: What Do You Know About Long-Acting Cabotegravir/Rilpivirine?Brian R. Wood, M.D.QuizLong-acting, intramuscular CAB/RPV is an excellent option for maintenance ART. Test your knowledge about the latest research and guidance on this regimen. Providing Quality HIV CareResearch Roundup: HIV Treatment Concerns Specific to WomenSusan Yox, RN, Ed.D.News1 Min ReadCisgender women living with HIV often have different clinical care needs from other patients, making it critical for providers to stay up to date on the latest research focusing specifically on women. All CoverageAntiretroviral TherapyHigh BMI May Warrant More Frequent LA-ART InjectionsBarbara JungwirthNews2 Min ReadSimulations suggest that morbidly obese people may be at risk of suboptimal trough concentrations of long-acting cabotegravir/rilpivirine, particularly for those receiving bimonthly injections. Antiretroviral TherapyHigh BMI May Warrant More Frequent LA-ART InjectionsBarbara JungwirthNews2 Min ReadSimulations suggest that morbidly obese people may be at risk of suboptimal trough concentrations of long-acting cabotegravir/rilpivirine, particularly for those receiving bimonthly injections. Antiretroviral TherapyCROI 2024 Is Coming. Here’s What Top HIV Clinicians Hope It Will DeliverAndy CarstensNews6 Min ReadFrom new developments in long-acting therapy to the latest on statin use in people with HIV, there is considerable excitement around the research about to be presented from March 3 to 6 in Denver. Antiretroviral TherapyCROI 2024 Is Coming. Here’s What Top HIV Clinicians Hope It Will DeliverAndy CarstensNews6 Min ReadFrom new developments in long-acting therapy to the latest on statin use in people with HIV, there is considerable excitement around the research about to be presented from March 3 to 6 in Denver. Antiretroviral TherapyCase Analyses Examine Viremia on Injectable HIV TreatmentBarbara JungwirthNews2 Min ReadThe investigation of loss of viral suppression in five people receiving injectable cabotegravir and rilpivirine found low drug levels and extensive resistance in all cases. Antiretroviral TherapyCase Analyses Examine Viremia on Injectable HIV TreatmentBarbara JungwirthNews2 Min ReadThe investigation of loss of viral suppression in five people receiving injectable cabotegravir and rilpivirine found low drug levels and extensive resistance in all cases. Antiretroviral TherapyImmune Recovery Lags in Older Adults With HIV, Chinese Study FindsBarbara JungwirthNews2 Min ReadWhile there was a consistent virological response across age groups in this study, older individuals showed poorer immune responses and experienced more antiretroviral side effects. Antiretroviral TherapyImmune Recovery Lags in Older Adults With HIV, Chinese Study FindsBarbara JungwirthNews2 Min ReadWhile there was a consistent virological response across age groups in this study, older individuals showed poorer immune responses and experienced more antiretroviral side effects. FDA-Approved HIV Medications192-Week Safety and Efficacy of Doravirine ReportedBarbara JungwirthNews3 Min ReadIn addition to similar efficacy and safety seen in prior results, doravirine also had little effect on lipids or other metabolic parameters. FDA-Approved HIV Medications192-Week Safety and Efficacy of Doravirine ReportedBarbara JungwirthNews3 Min ReadIn addition to similar efficacy and safety seen in prior results, doravirine also had little effect on lipids or other metabolic parameters. Managing HIV Drug ResistanceStudy Bite: Epidemiology, Outcomes of Limited HIV Treatment OptionsBarbara JungwirthNews2 Min ReadNew data on the prevalence of exhausted or limited treatment options in people with HIV is provided by a large study in Europe and Australia. Managing HIV Drug ResistanceStudy Bite: Epidemiology, Outcomes of Limited HIV Treatment OptionsBarbara JungwirthNews2 Min ReadNew data on the prevalence of exhausted or limited treatment options in people with HIV is provided by a large study in Europe and Australia. Managing People Newly Diagnosed With HIVStudy Bite: CD4:CD8 Ratio Recovery Slows Among Older People Starting HIV TreatmentBarbara JungwirthNews3 Min ReadIn people who were virally suppressed, those beginning treatment after age 60 had reduced CD4:CD8 recovery, when compared with people starting treatment in their 30s. Managing People Newly Diagnosed With HIVStudy Bite: CD4:CD8 Ratio Recovery Slows Among Older People Starting HIV TreatmentBarbara JungwirthNews3 Min ReadIn people who were virally suppressed, those beginning treatment after age 60 had reduced CD4:CD8 recovery, when compared with people starting treatment in their 30s. Managing HIV Drug ResistanceQuiz Yourself: HIV Resistance Testing OptionsEileen Scully, M.D., Ph.D.QuizOptions for HIV drug resistance testing have expanded. We’ll help you understand which tests to order in various clinical scenarios to help you provide the best care for your patients. Managing HIV Drug ResistanceQuiz Yourself: HIV Resistance Testing OptionsEileen Scully, M.D., Ph.D.QuizOptions for HIV drug resistance testing have expanded. We’ll help you understand which tests to order in various clinical scenarios to help you provide the best care for your patients. First-Line HIV TreatmentStudy Bite: With Immediate Treatment of HIV, Semen Viral Load Drops RapidlyBarbara JungwirthNews3 Min ReadIdentifying acute HIV infections and treating them quickly enhances viral suppression in semen, reports a small study in Peru. First-Line HIV TreatmentStudy Bite: With Immediate Treatment of HIV, Semen Viral Load Drops RapidlyBarbara JungwirthNews3 Min ReadIdentifying acute HIV infections and treating them quickly enhances viral suppression in semen, reports a small study in Peru. Perinatal Care & PregnancyStudy Bite: B/F/TAF Safe, Effective During PregnancyBarbara JungwirthNews2 Min ReadPregnant women with HIV treated with once-daily B/F/TAF maintained virologic suppression into the postpartum follow-up period, with no dose adjustment needed. Perinatal Care & PregnancyStudy Bite: B/F/TAF Safe, Effective During PregnancyBarbara JungwirthNews2 Min ReadPregnant women with HIV treated with once-daily B/F/TAF maintained virologic suppression into the postpartum follow-up period, with no dose adjustment needed. Antiretroviral TherapyLong-Acting Cabotegravir/Rilpivirine Is Effective in People With HIV ViremiaDavid Alain Wohl, M.D.Commentary5 Min ReadOver a median of 33 weeks of follow-up, viral suppression was achieved in 95% patients who started with a detectable viral load. Antiretroviral TherapyLong-Acting Cabotegravir/Rilpivirine Is Effective in People With HIV ViremiaDavid Alain Wohl, M.D.Commentary5 Min ReadOver a median of 33 weeks of follow-up, viral suppression was achieved in 95% patients who started with a detectable viral load. Stigma & DiscriminationRacial and Ethnic Disparities: Who Gets Modern HIV Treatment in the U.S.?David Alain Wohl, M.D.Commentary4 Min ReadGuidelines, insurance, and prescriber awareness all matter when it comes to reducing disparities in access to advances in HIV treatment. Stigma & DiscriminationRacial and Ethnic Disparities: Who Gets Modern HIV Treatment in the U.S.?David Alain Wohl, M.D.Commentary4 Min ReadGuidelines, insurance, and prescriber awareness all matter when it comes to reducing disparities in access to advances in HIV treatment.